A Population Pharmacokinetic Analysis of Zanamivir in Subjects with Experimental and Naturally Occurring Influenza: Effects of Formulation and Route of Administration

Journal of Clinical Pharmacology

Volumn 40, Issue 3, 2000, Pages 242-249

  Peng, Amy W ^a   Hussey, Elizabeth K ^a   Moore, Katy H P ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GUANIDINE DERIVATIVE; PYRAN DERIVATIVE; SIALIC ACID DERIVATIVE; ZANAMIVIR;

ADULT; ALGORITHM; ARTICLE; BIOLOGICAL MODEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; INFLUENZA; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; MALE; METABOLISM; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; ADMINISTRATION, INTRANASAL; ADULT; ALGORITHMS; ANTIVIRAL AGENTS; DOUBLE-BLIND METHOD; FEMALE; GUANIDINES; HUMANS; INFLUENZA, HUMAN; MALE; MODELS, BIOLOGICAL; PYRANS; SIALIC ACIDS; ZANAMIVIR;

EID: 0034145687     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700022008900     Document Type: Article

References (15)

1. Betts R: Influenza virus, in: Mandell G, Bennett J, Dolin R (eds.), Principles and Practice of Infectious Diseases. New York: Churchill Livingstone, 1995;1546-1567.
2. Nicholson K: Clinical features of influenza. Sem Resp Inf 1992;7: 26-37.
3. Wade RC: "Flu" and structure-based drug design. Structure 1997; 5(9):1139-1145.
4. Hayden FG: Amantadine and rimantadine resistance in influenza A viruses. Curr Op Infect Dis 1994;7(6):674-677.
5. Zimmerman RK, Ruben FL, Ahwesh ER: Influenza, influenza vaccine and amantadine/rimantadine. J Fam Prac 1997;45(2):107-122.
6. Calfee DP, Hayden FG: New approaches to influenza chemotherapy. Drugs 1998;56(4):537-553.
7. Waghorn SL, Goa KL: Zanamivir. Drugs 1998;55(5):721-725; discussion 725-727.
8. von Itzstein M, Wu WY, Kok GB, Pegg MS, Dyason JC, Jin B, et al: Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363(6428):418-423.
9. Ryan DM, Ticehurst J, Dempsey MH, Penn CR: Inhibition of influenza virus replication in mice by GG167 (4-guanidino- 2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994;38(10):2270-2275.
10. Cass L, Efthymiopoulos C, Bye A: Review of the pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal dosing in healthy volunteers. Clin Pharmacokinet 1999;36(Suppl. 1):1-11.
11. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK: Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. J Am Med Assoc 1996;275(4):295-299.
12. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, et al: Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. GG167 Influenza Study Group. N Engl J Med 1997;337(13):874-880.
13. MIST Group: Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998;352:1877-1881.
14. Grosse C, Morris D, Selinger K: Determination of GR121167X (zanamivir) in human serum spray by ionspray LC/MS/MS. Paper presented at the Sixth International Symposium on Pharmaceutical and Biomedical Analysis, St. Louis, MO, 1995, vol. M-P, p. A25.
15. Hayden F, Lobo M, Hussey E, Eason C: Efficacy of intranasal zanamivir in experimental human influenza A and B virus infection, in: Brown L, Hampson A, Webster A (eds.): Options for Control of Influenza III. Amsterdam: Elsevier, 1996;718-725.